Cladribine (2-CdA)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CLADRIBINE |
|---|---|
| Type | Drug |
| Aliases | CladribineLeustatinLitakКладрибін |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-HCL |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Purine analogue (deoxyadenosine analogue) |
|---|---|
| Mechanism | Resistant to deamination by ADA; phosphorylated to active triphosphate that incorporates into DNA, inhibits DNA repair, and induces apoptosis. Selectively cytotoxic to lymphocytes. |
| Typical dosing | HCL 1L: 0.09 mg/kg/day continuous IV × 7 days (single course often curative); SC: 0.14 mg/kg/day × 5 days alternative |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Severe lymphocyte depletion → opportunistic infections (PJP) for ≥1 year post
Notes
Single 7-day course produces durable CR in >85% of HCL — one of the most effective single-agent regimens in oncology. Mandatory PJP prophylaxis (cotrimoxazole) and HSV prophylaxis (acyclovir) for ≥1 year post — profound lasting CD4 lymphopenia.
Used By
Regimens
REG-CLADRIBINE-SINGLE- Cladribine single 7-day course